HQY Quote, Financials, Valuation and Earnings

HealthStream has a net margin of 8.46% compared to HealthEquity's net margin of 6.59%. HealthEquity's return on equity of 4.59% beat HealthStream's return on equity of 5.72%.

HealthEquity has a consensus price target of $113.29, signalling upside risk potential of 26.97%. On the other hand HealthStream has an analysts' consensus of $35.00 which suggests that it could grow by 9.72%. Given that HealthEquity has higher upside potential than HealthStream, analysts believe HealthEquity is more attractive than HealthStream.

HealthEquity has a beta of 0.617, which suggesting that the stock is 38.323% less volatile than S&P 500. In comparison HealthStream has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.556%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HealthStream offers a yield of 0.36% to investors and pays a quarterly dividend of $0.03 per share. HealthEquity pays -- of its earnings as a dividend. HealthStream pays out 17.01% of its earnings as a dividend. HealthStream's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity quarterly revenues are $311.8M, which are larger than HealthStream quarterly revenues of $74.2M. HealthEquity's net income of $26.4M is higher than HealthStream's net income of $4.9M. Notably, HealthEquity's price-to-earnings ratio is 81.85x while HealthStream's PE ratio is 48.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.60x versus 3.34x for HealthStream. Usually stocks with elevated PS ratios are considered overvalued.

Schrodinger has a net margin of 8.46% compared to HealthEquity's net margin of -45.54%. HealthEquity's return on equity of 4.59% beat Schrodinger's return on equity of -38.87%.

HealthEquity has a consensus price target of $113.29, signalling upside risk potential of 26.97%. On the other hand Schrodinger has an analysts' consensus of $30.80 which suggests that it could grow by 49.52%. Given that Schrodinger has higher upside potential than HealthEquity, analysts believe Schrodinger is more attractive than HealthEquity.

HealthEquity has a beta of 0.617, which suggesting that the stock is 38.323% less volatile than S&P 500. In comparison Schrodinger has a beta of 1.624, suggesting its more volatile than the S&P 500 by 62.426%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrodinger offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity pays -- of its earnings as a dividend. Schrodinger pays out -- of its earnings as a dividend.

HealthEquity quarterly revenues are $311.8M, which are larger than Schrodinger quarterly revenues of $88.3M. HealthEquity's net income of $26.4M is higher than Schrodinger's net income of -$40.2M. Notably, HealthEquity's price-to-earnings ratio is 81.85x while Schrodinger's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.60x versus 7.21x for Schrodinger. Usually stocks with elevated PS ratios are considered overvalued.

Simulations Plus has a net margin of 8.46% compared to HealthEquity's net margin of 1.09%. HealthEquity's return on equity of 4.59% beat Simulations Plus's return on equity of 4.58%.

HealthEquity has a consensus price target of $113.29, signalling upside risk potential of 26.97%. On the other hand Simulations Plus has an analysts' consensus of $49.40 which suggests that it could grow by 105.83%. Given that Simulations Plus has higher upside potential than HealthEquity, analysts believe Simulations Plus is more attractive than HealthEquity.

HealthEquity has a beta of 0.617, which suggesting that the stock is 38.323% less volatile than S&P 500. In comparison Simulations Plus has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.602%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus offers a yield of 1% to investors and pays a quarterly dividend of $0.06 per share. HealthEquity pays -- of its earnings as a dividend. Simulations Plus pays out 48.18% of its earnings as a dividend. Simulations Plus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity quarterly revenues are $311.8M, which are larger than Simulations Plus quarterly revenues of $18.9M. HealthEquity's net income of $26.4M is higher than Simulations Plus's net income of $206K. Notably, HealthEquity's price-to-earnings ratio is 81.85x while Simulations Plus's PE ratio is 60.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.60x versus 6.55x for Simulations Plus. Usually stocks with elevated PS ratios are considered overvalued.